Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYS6062 in Advanced Solid Tumors
NCT07897227Phase 2Not yet recruiting
- Sponsor
- CSPC Megalith Biopharmaceutical Co., Ltd.
- Start
- Nov 2026
- Primary completion
- May 2029
01
Overview
Phase 2, open-label, single-arm trial of SYS6062 in solid tumor, gastric cancer (GC), colorectal cancer (CRC) and 1 more, sponsored by CSPC Megalith Biopharmaceutical Co., Ltd. Primary endpoints: Adverse events and serious adverse events up to 3 years, Dose-limiting toxicities and 1 more. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
SYS6062
03
Conditions
solid tumorgastric cancer (GC)colorectal cancer (CRC)pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT07897227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07897227.